Category: Ideas
-
DocuSign, Emcore, Guidewire Software And A Health Care Stock On CNBC’s ‘Final Trades’
in IdeasOn CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said DocuSign, Inc. (NASDAQ:DOCU) crushed its last quarter and is expected to report another strong quarter. This is a “great entry point,” she added. On Dec. 5, DocuSign reported third-quarter revenue of $754.8 million, beating the consensus estimate of $745.26 million. The company…
-
Understanding Microsoft’s Position In Software Industry Compared To Competitors
in IdeasIn the fast-paced and highly competitive business world of today, conducting thorough company analysis is essential for investors and industry observers. In this article, we will conduct an extensive industry comparison, evaluating Microsoft (NASDAQ:MSFT) in relation to its major competitors in the Software industry. Through a detailed examination of key financial metrics, market standing, and…
-
Top 3 Industrials Stocks Which Could Rescue Your Portfolio This Month
in IdeasThe most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better…
-
Top 3 Health Care Stocks That Could Blast Off This Quarter
in IdeasThe most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a…
-
$1000 Invested In Dell Technologies 5 Years Ago Would Be Worth This Much Today
in IdeasDell Technologies (NYSE:DELL) has outperformed the market over the past 5 years by 22.02% on an annualized basis producing an average annual return of 34.36%. Currently, Dell Technologies has a market capitalization of $76.85 billion. Buying $1000 In DELL: If an investor had bought $1000 of DELL stock 5 years ago, it would be worth…
-
XRP’s Price Increased More Than 11% Within 24 hours
in IdeasXRP’s (CRYPTO: XRP) price has increased 11.58% over the past 24 hours to $2.86. Over the past week, XRP has experienced an uptick of over 24.0%, moving from $2.32 to its current price. As it stands right now, the coin’s all-time high is $3.40. The chart below compares the price movement and volatility for XRP…
-
A Better Way To Play Bitcoin?
in IdeasMicroStrategy As A Levered Play On Bitcoin In recent years, MicroStrategy, Inc. (NASDAQ:MSTR) has emerged as a essentially a levered play on Bitcoin. Over the last year, for example, MicroStrategy was up 468%, while Bitcoin was up 105%. MicroStrategy’s Bitcoin Balance Sheet Strategy. What drove MicroStrategy’s outperformance is its Bitcoin Balance Sheet Strategy. MicroStrategy CEO Michael Saylor is…
-
Delta Air Lines, Walgreens And 3 Stocks To Watch Heading Into Friday
in IdeasWith U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Delta Air Lines Inc. (NYSE:DAL) to report quarterly earnings at $1.76 per share on revenue of $14.21 billion before the opening bell, according to data from Benzinga Pro. Delta…
-
$1000 Invested In Marathon Petroleum 10 Years Ago Would Be Worth This Much Today
in IdeasMarathon Petroleum (NYSE:MPC) has outperformed the market over the past 10 years by 2.51% on an annualized basis producing an average annual return of 13.88%. Currently, Marathon Petroleum has a market capitalization of $45.74 billion. Buying $1000 In MPC: If an investor had bought $1000 of MPC stock 10 years ago, it would be worth…
-
Sana Biotechnology Stock Surges Over 200% On Wednesday – Here’s Why
in IdeasOn Tuesday, Sana Biotechnology Inc (NASDAQ:SANA) released the initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, into a type 1 diabetes patient without the use of any immunosuppression. The study was conducted in partnership with Uppsala University Hospital. Results of the study at…